Amgen Inc. Impairment of Intangible Assets, Finite-lived
Amgen Inc. (AMGN) reported Impairment of Intangible Assets, Finite-lived of $1.20 billion for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsFinitelived · last filed 2026-02-13
- Amgen Inc. impairment of intangible assets, finite-lived for the quarter ending 2025-12-31 was $0.00.
- Amgen Inc. impairment of intangible assets, finite-lived for the quarter ending 2025-09-30 was $400.00M.
- Amgen Inc. impairment of intangible assets, finite-lived for fiscal 2025 was $1.20B.
| Period end | Impairment of Intangible Assets, Finite-lived 3 month | Impairment of Intangible Assets, Finite-lived 6 month | Impairment of Intangible Assets, Finite-lived 9 month | Impairment of Intangible Assets, Finite-lived 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $400.00M derived: sum of 2 quarters · filed 2026-02-13 | $1.20B 10-K · filed 2026-02-13 | |
| 2025-09-30 | $400.00M 10-Q · filed 2025-11-05 | $1.20B 10-Q · filed 2025-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |